Related Experiment Video

Updated: Dec 28, 2025

Dual CRISPR-Interference Strategy for Targeting Synthetic Lethal Interactions Between Non-Coding RNAs in Cancer Cells
07:23

Dual CRISPR-Interference Strategy for Targeting Synthetic Lethal Interactions Between Non-Coding RNAs in Cancer Cells

Published on: May 30, 2025

991

Circular RNAs: Potential Regulators of Treatment Resistance in Human Cancers

Shivapriya Jeyaraman1, Ezanee Azlina Mohamad Hanif1, Nurul Syakima Ab Mutalib1

  • 1UKM Medical Molecular Biology Institute (UMBI), UKM Medical Center, Kuala Lumpur, Malaysia.

Frontiers in Genetics
|February 13, 2020
PubMed

Insights

Circular RNAs (circRNAs) are emerging as key regulators in human cancers, particularly in treatment resistance. Their unique stability and disease-specific expression offer new avenues for managing cancer therapy resistance.

Area of Science:

  • Molecular Biology
  • Oncology
  • Genomics

Background:

  • Circular RNAs (circRNAs) were initially dismissed as non-functional "junk" RNA.
  • Recent advancements in high-throughput technologies have revealed their significant regulatory roles in human diseases, especially cancer.
  • Unique properties like stability, disease-specific expression, and tissue abundance make circRNAs promising for medical applications.

Purpose of the Study:

  • To review the emerging role of circular RNAs (circRNAs) in regulating treatment resistance in human cancers.
  • To explore the potential of circRNAs in cancer therapy resistance management based on their molecular interactions and regulatory networks.

Main Methods:

  • Literature review focusing on recent studies of circRNAs in cancer.
  • Analysis of circRNA involvement in key pathways associated with treatment resistance.
  • Examination of circRNA-disease associations and regulatory networks in cancer.

Main Results:

  • Circular RNAs (circRNAs) are increasingly recognized for their involvement in various types of cancer treatment resistance.
  • Specific pathways activated by circRNAs have been implicated in the development of resistance.
  • The role of circRNAs in treatment resistance is a nascent field with significant potential for future validation.

Conclusions:

  • Circular RNAs (circRNAs) show potential as regulators of cancer treatment resistance.
  • Understanding circRNA mechanisms may offer novel strategies for overcoming treatment resistance in oncology.
  • Further research is needed to fully validate the clinical utility of circRNAs in cancer therapy.
Keywords:
RNA splicingbiomarkerchemoresistancenon-coding RNAsradioresistance

More Related Videos

In Silico Identification and Characterization of circRNAs During Host-Pathogen Interactions10:27

In Silico Identification and Characterization of circRNAs During Host-Pathogen Interactions

Published on: October 21, 2022

1.9K
Identification of Circular RNAs using RNA Sequencing08:25

Identification of Circular RNAs using RNA Sequencing

Published on: November 14, 2019

12.6K

Related Concept Videos

Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.6K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
4.5K
Abnormal Proliferation02:23

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
5.0K
Types of RNA01:23

Types of RNA

Overview
Three main types of RNA are involved in protein synthesis: messenger RNA (mRNA), transfer RNA (tRNA), and ribosomal RNA (rRNA). These RNAs perform diverse functions and can be broadly classified as protein-coding or non-coding RNA. Non-coding RNAs play important roles in the regulation of gene expression in response to developmental and environmental changes. Non-coding RNAs in prokaryotes can be manipulated to develop more effective antibacterial drugs for human or animal use.
RNA...
72.3K
lncRNA - Long Non-coding RNAs02:39

lncRNA - Long Non-coding RNAs

In humans, more than 80% of the genome gets transcribed. However, only around 2% of the genome codes for proteins. The remaining part produces non-coding RNAs which includes ribosomal RNAs, transfer RNAs, telomerase RNAs, and regulatory RNAs, among other types. A large number of regulatory non-coding RNAs have been classified into two groups depending upon their length – small non-coding RNAs, such as microRNA, which are less than 200 nucleotides in length, and long non-coding RNA...
9.6K
Negative Regulator Molecules01:23

Negative Regulator Molecules

Positive regulators allow a cell to advance through cell cycle checkpoints. Negative regulators have an equally important role as they terminate a cell’s progression through the cell cycle—or pause it—until the cell meets specific criteria.
38.1K